REGN3124-PBD a Novel EGFRvIII-selective ADC Shows Promise Against Glioblastoma Multiforme Patient-derived Xenografts
Glioblastoma Multiforme (GBM) is a highly aggressive primary malignant brain tumor with few specific molecular targets and poor therapeutic...
Preclinical Study Supports Continued Evaluation of CD25-targeted ADC in Selected Advanced Solid Tumors
Preclinical data for camidanlumab tesirine (formerly ADCT-301; ADC Therapeutics), published in the Journal for ImmunoTherapy of Cancer, the online...